Free Trial
NASDAQ:ENTO

Entero Therapeutics (ENTO) Stock Price, News & Analysis

Entero Therapeutics logo
$0.36 -0.02 (-6.20%)
Closing price 04:00 PM Eastern
Extended Trading
$0.37 +0.01 (+1.40%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Entero Therapeutics Stock (NASDAQ:ENTO)

Key Stats

Today's Range
$0.36
$0.40
50-Day Range
$0.38
$0.59
52-Week Range
$0.21
$0.93
Volume
155,026 shs
Average Volume
965,450 shs
Market Capitalization
$1.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ENTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ENTO Stock News Headlines

Entero Therapeutics Inc ENTO
Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.
Entero Therapeutics Delays 10-K Filing
Entero Therapeutics names Richard Paolone as interim CEO
See More Headlines

ENTO Stock Analysis - Frequently Asked Questions

Entero Therapeutics' stock was trading at $0.6220 at the start of the year. Since then, ENTO shares have decreased by 41.3% and is now trading at $0.3649.

Entero Therapeutics, Inc. (NASDAQ:ENTO) announced its quarterly earnings data on Thursday, May, 15th. The company reported ($0.21) earnings per share (EPS) for the quarter.

Shares of ENTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Entero Therapeutics investors own include Conduit Pharmaceuticals (CDT), BIOLASE (BIOL), Cyclacel Pharmaceuticals (CYCC), Dare Bioscience (DARE), PMGC (ELAB), TRACON Pharmaceuticals (TCON) and Tempest Therapeutics (TPST).

Company Calendar

Last Earnings
5/15/2025
Today
8/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ENTO
Previous Symbol
NASDAQ:ENTO
CIK
1604191
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$18.06 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-1,063.82%
Return on Assets
-26.06%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.90
Quick Ratio
2.90

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.82) per share
Price / Book
-0.47

Miscellaneous

Outstanding Shares
4,766,000
Free Float
4,730,000
Market Cap
$1.85 million
Optionable
N/A
Beta
0.80
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:ENTO) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners